Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine + finolitimab + bevacizumab vs capecitabine as adjuvant therapy in high-risk biliary tract cancer
ChiCTR2500112470Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of capecitabine + finolitimab + bevacizumab and capecitabine in biliary cancer (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: recurrence-free survival. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
capecitabine + finolitimab + bevacizumabcapecitabine
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2500112470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112470.